Investing.com - BioXcel Therapeutics (NASDAQ: BTAI) reported first quarter EPS of $-0.76, $0.16 better than the analyst estimate of $-0.92. Revenue for the quarter came in at $376K versus the consensus estimate of $742.86K.
BioXcel Therapeutics's stock price closed at $2.90. It is down -10.49% in the last 3 months and down -86.50% in the last 12 months.
BioXcel Therapeutics saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See BioXcel Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, BioXcel Therapeutics's Financial Health score is "weak performance".
Check out BioXcel Therapeutics's recent earnings performance, and BioXcel Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar